Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

导出 OA

翻译打印收藏纠错

作者： Brendan J,Guercio ^[1] ; Michal,Sarfaty ^[2] ; Min Yuen,Teo ^[3] ; Neha,Ratna ^[4] ; Cihan,Duzgol ^[1] ; Samuel A,Funt ^[5] ; Chung-Han,Lee ^[1] ; David H,Aggen ^[6] ; Ashley M,Regazzi ^[1] ; Ziyu,Chen ^[5] ; Michael,Lattanzi ^[1] ; Hikmat A,Al-Ahmadie ^[5] ; A Rose,Brannon ^[1] ; Ronak,Shah ^[5] ; Carissa,Chu ^[1] ; Andrew T,Lenis ^[7] ; Eugene,Pietzak ^[8] ; Bernard H,Bochner ^[9] ; Michael F,Berger ^[7] ; David B,Solit ^[7] ; Jonathan E,Rosenberg ^[10] ; Dean F,Bajorin ^[11] ; Gopa,Iyer ^[5]

作者单位： Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ^[1] Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. ^[2] Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel. ^[3] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[4] Weill Cornell Medical College, New York, New York. ^[5] Commonwealth Radiology Associates, Andover, Massachusetts. ^[6] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. ^[7] Texas Oncology, Austin, Texas. ^[8] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ^[9] Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. ^[10] Department of Urology, Columbia University Irving Medical Center, New York, New York. ^[11]

主题词人类(Humans);膀胱肿瘤(Urinary Bladder Neoplasms);癌, 移行细胞(Carcinoma, Transitional Cell);受体, 成纤维细胞生长因子, 3型(Receptor, Fibroblast Growth Factor, Type 3);治疗结果(Treatment Outcome);基因组学(Genomics)

DOI 10.1158/1078-0432.CCR-23-1283

PMID 37682528

发布时间 2024-07-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交